SGLT2阻害薬で6年透析導入を遅延できるか？
長澤将
00:00 | 00:00
上手く使えば腎予後が1.2-1.4倍になる印象を持っています。
McEwan P, Gabb PD, Davis JA, Sanchez JJG, Sjöström CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant. 2024 May 10:gfae106. doi: 10.1093/ndt/gfae106. Epub ahead of print. PMID: 38730538.
Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. PMID: 37529652; PMCID: PMC10387399.
McEwan P, Gabb PD, Davis JA, Sanchez JJG, Sjöström CD, Barone S, Kashioulis P, Ouwens M, Cassimaty S, Correa-Rotter R, Rossing P, Wheeler DC, Heerspink HJL. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant. 2024 May 10:gfae106. doi: 10.1093/ndt/gfae106. Epub ahead of print. PMID: 38730538.
Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. PMID: 37529652; PMCID: PMC10387399.
この記事が気に入ったらサポートをしてみませんか？